expanding-but-regulatory-constrained
Raised in three tranches through Jul-2025 (cumulative $93M) and publicly launched its therapy chatbot Ash (Jul-2025) with a free iOS/Android app after an 18-month build and 50,000-user beta -- genuine product/capital expansion. But Jan-2026 it pulled Ash out of the UK market over regulatory concerns, and the FDA was separately reviewing a therapy-chatbot risk framework (Nov-2025) -- so expansion is now running into real regulatory friction, not a clean growth story. No new funding round found since Jul-2025 despite an active 2026 search.
Sourced figures 3
- Slingshot AI — Press page (aggregating AP/Forbes/Behavioral Health Business coverage) Slingshot AI launches Ash, 'the first AI designed for therapy', after 18 months development and a 50,000-user beta; free iOS/Android app
- STAT News via Google News RSS Slingshot pulls therapy chatbot Ash out of the U.K. over regulatory concerns
- coverage via Google News RSS (FDA advisory context) FDA advisers examined risks associated with therapy chatbots, considering a regulatory framework
the working
Basis
Raised in three tranches through Jul-2025 (cumulative $93M) and publicly launched its therapy chatbot Ash (Jul-2025) with a free iOS/Android app after an 18-month build and 50,000-user beta -- genuine product/capital expansion. But Jan-2026 it pulled Ash out of the UK market over regulatory concerns, and the FDA was separately reviewing a therapy-chatbot risk framework (Nov-2025) -- so expansion is now running into real regulatory friction, not a clean growth story. No new funding round found since Jul-2025 despite an active 2026 search.
Threads 1
A claim is one metric we assert about a node — the value is the summary, this page is the receipt. Sourced from kestrel; supersedes-history not yet shown. Back to Slingshot AI.